Nonsteroidal anti-inflammatory drugs as anticancer agents: Mechanistic, pharmacologic, and clinical issues

Journal of the National Cancer Institute

Volumn 94, Issue 4, 2002, Pages 252-266

  Thun, Michael J ^a   Jane Henley, S ^a   Patrono, Carlo ^b  

^a AMERICAN CANCER SOCIETY   (United States)

^b UNIVERSITY OF CHIETI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTINEOPLASTIC AGENT; AZOXYMETHANE; CELECOXIB; CURCUMIN; CYCLOOXYGENASE 1; EFLORNITHINE; ETORICOXIB; FOLIC ACID; IBUPROFEN; INDOMETACIN; KETOPROFEN; KETOROLAC; NAPROXEN; NEW DRUG; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM; PLACEBO; PROSTACYCLIN; PROSTAGLANDIN E2; ROFECOXIB; SELENIUM; STARCH; SULINDAC SULFONE; TRASTUZUMAB; VALDECOXIB;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; CANCER PREVENTION; CLINICAL RESEARCH; CLINICAL STUDY; COLORECTAL CANCER; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG EFFICACY; DRUG MECHANISM; ENZYME INHIBITION; GASTROINTESTINAL TOXICITY; HUMAN; HUMAN CELL; MEDICAL LITERATURE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; THROMBOSIS;

EID: 0037138743     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/94.4.252     Document Type: Review

References (218)

1. Cyclooxygenase-2 inhibitors in tumorigenesis
2. Cyclooxygenase-2 inhibitors in tumorigenesis
3. Chemoprevention of colorectal cancer
4. Excess risk of lymphomas, leukemia and myeloma in patients with rheumatoid arthritis
5. Incidence of cancer among patients with rheumatoid arthritis
6. Aspirin use and reduced risk of fatal colon cancer
7. Aspirin use and risk of fatal cancer
8. Risk factors for colorectal cancer in patients with ulcerative colitis: A case-control study
9. Aspirin use and lung, colon, and breast cancer incidence in a prospective study
10. Aspirin use and the risk for colorectal cancer and adenoma in male health professionals
11. Dietary factors and risk of colon cancer
12. Aspirin and the risk of colorectal cancer in women
13. Alcohol, low-methionine-low-folate diets, and risk of colon cancer in men
14. Use of nonsteroidal anti-inflammatory drugs and incidence of colorectal cancer
15. Colorectal cancer prevention by non-steroidal anti-inflammatory drugs: Effects of dosage and timing
16. Effect of anti-inflammatory drugs on overall risk of common cancer: Case-control study in general practice research database
17. Reduced risk of colorectal cancer among long-term users of aspirin and nonaspirin nonsteroidal anti-inflammatory drugs
18. Colorectal cancer risk, chronic illnesses, operations, and medications: Case control results from the Melbourne Colorectal Cancer Study
19. A hypothesis: Nonsteroidal anti-inflammatory drugs reduce the incidence of large-bowel cancer
20. Aspirin use, cancer, and polyps of the large bowel
21. Aspirin and nonsteroidal anti-inflammatory drug use and the risk of subsequent colorectal cancer
22. Nonsteroidal antiinflammatory drugs and colorectal cancer
23. Diseases preceding colon cancer: A case-control study among veterans
24. Nonsteroidal anti-inflammatory drug use and protection against colorectal cancer in women
25. Risk factors of colorectal cancer in inflammatory bowel disease
26. Aspirin and colorectal cancer
27. Nonsteroidal antiinflammatory drug use and reduced risk of large bowel carcinoma
28. NSAIDs and risk of colorectal cancer according to presence or absence of family history of the disease
29. Reduced risk of large-bowel adenomas among aspirin users
30. Reduced incidence of colorectal adenoma among long-term users of nonsteroidal antiinflammatory drugs: A pooled analysis of published studies and a new population-based study
31. Effect of aspirin and non-steroidal anti-inflammatory drugs on colorectal adenomas: Case-control study of subjects participating in the Nottingham faecal occult blood screening programme
32. Aspirin and other nonsteroidal anti-inflammatory drugs and risk of colorectal adenomatous polyps among endoscoped individuals
33. Long-term use of nonsteroidal antiinflammatory drugs and other chemopreventors and risk of subsequent colorectal neoplasia
34. Aspirin and nonsteroidal anti-inflammatory agents and risk for colorectal adenomas
35. Long-term use of nonsteroidal antiinflammatory drugs and the risk of colorectal adenomas
36. Low incidence of colorectal cancer in patients with rheumatoid arthritis
37. Drugs and colon cancer
38. Aspirin use and chronic diseases: A cohort study of the elderly
39. Aspirin use and incidence of large-bowel cancer in a California retirement community [letter]
40. Aspirin and colorectal cancer: The Leisure World cohort revisited
41. Sulindac causes regression of rectal polyps in familial adenomatous polyposis
42. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis
43. Randomized controlled trial of the effect of sulindac on duodenal and rectal polyposis and cell proliferation in patients with familial adenomatous polyposis
44. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis
45. Aspirin as prophylaxis against colorectal cancer
46. Non-steroidal anti-inflammatory drugs
47. Annual report to the nation on the status of cancer (1973 through 1998), featuring cancers with recent increasing trends
48. Cancer statistics, 2001
49. Hereditary colorectal cancer syndromes
50. Collaborative overview of randomised trials of antiplatelet therapy-I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients
51. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients
52. Platelet-active drugs: The relationships among dose, effectiveness, and side effects
53. Aspirin as an antiplatelet drug
54. Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial
55. Thrombosis prevention trial: Randomised trial of low-intensity oral anti-coagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk
56. Final report on the aspirin component of the ongoing Physicians' Health Study
57. Gastrointestinal toxicity of non-steroidal antiinflammatory drugs
58. History of aspirin and its mechanism of action
59. Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2
60. Mitogen-inducible prostaglandin G/H synthase: A new target for nonsteroidal antiinflammatory drugs
61. Lipid-derived autacoids
62. Analgesic-antipyretic and antiinflammatory agents and drugs employed in the treatment of gout
63. The coxibs, selective inhibitors of cyclooxygenase-2
64. Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects
65. Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man
66. COX-1-sparing NSAIDs-is the enthusiasm justified?
67. COX-1, COX-2, and COX-3 and the future treatment of chronic inflammatory disease
68. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis
69. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: The human pharmacology of a selective inhibitor of COX-2 [erratum appears in Proc Natl Acad Sci U S A 1999;96:5890]
70. Selective cyclooxygenase-2 inhibition by nimesulide in man
71. Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids
72. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs
73. Combinatorial chemoprevention of intestinal neoplasia
74. Combinations for cancer prevention
75. Lovastatin augments sulindac-induced apoptosis in colon cancer cells and potentiates chemopreventive effect of sulindac
76. 2 levels in rat colon
77. Chemoprevention of colon carcinogenesis by concurrent administration of piroxicam, a nonsteroidal antiinflammatory drug with D,L-α-difluromethylornithine, an ornithine decarboxylase inhibitor, in diet
78. Chemo-prevention of colon carcinogenesis by dietary administration of piroxicam α-difuoromethylornithine, 16 α-fluoro-5-androsten-17-one, and ellagic acid individually and in combination
79. Chemoprevention of colon carcinogenesis by sulindac, a nonsteroidal anti-inflammatory agent
80. Proceedings: Prostaglandins in human colonic carcinoma
81. Prostaglandins and cancer: An update
82. Induction of colon tumors in 1,2-dimethylhydrazine-resistant Lobund Wistar rats by methylazoxymethanol acetate
83. Indomethacin treatment of rats with dimenthylhydrazine-induced intestinal tumors
84. Effect of indomethacin on intestinal tumors induced in rats by the acetate derivative of dimethylnitrosoamine
85. Treatment of chemically-induced intestinal cancers with indomethacin
86. Prolonged antitumor effect of indomethacin on autochthonous intestinal tumors in rats
87. The suppressive effect of piroxicam on autochthonous intestinal tumors in the rat
88. Effect of piroxicam on primary intestinal tumors induced in rats by N-methylnitrosourea
89. Antitumor effect of indomethacin in rats with autochthonous intestinal tumors
90. Prevention and treatment of primary intestinal tumors in rats by piroxicam
91. Antitumor activity of indomethacin on methylazoxymethanol-induced large bowel tumors in rats
92. Inhibition of development of methylnitrosourea-induced rat colon tumors by indomethacin treatment
93. Inhibition of development of methylnitrosourea-induced rat colonic tumors by peroral administration of indomethacin
94. Inhibition of initiation and promotion by N-methylnitrosourea-induced colon carcinogenesis in rats by non-steroid anti-inflammatory agent indomethacin
95. 2) against indomethacin
96. Influence of various prostaglandin synthesis inhibitors on DMH-induced rat colon cancer
97. Inhibition of intestinal carcinogenesis in rats: Effect of difluoromethylornithine with piroxicam or fish oil
98. Dose-related inhibition of colon carcinogenesis by dietary piroxicam, a nonsteroidal antiinflammatory drug, during different stages of rat colon tumor development
99. Inhibition of colon carcinogenesis by prostaglandin synthesis inhibitors and related compounds
100. Inhibitory effect of aspirin on azoxymethane-induced colon carcinogenesis in F344 rats
101. Effects of aspirin on 1,2-dimethylhydrazine-induced colonic carcinogenesis
102. A protective effect of sulindac against chemically-induced primary colonic tumours in mice
103. The effect of sulindac on colonic tumor formation in dimethylhydrazine-treated mice
104. Sulindac inhibits the rate of growth and appearance of colon tumors in the rat
105. Aspirin reduces the incidence of colonic carcinoma in the dimethydrazine rat animal model
106. Chemoprevention of azoxmethane-induced aberrant crypt foci and colon tumors in p53-deficient mice by sulindac [abstract]
107. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis
108. Effect of duration of treatment with piroxicam on azoxymethane-induced colon cancer, aberrant crypt foci, apoptosis and cell proliferation in rats [abstract]
109. Determination of an optimal dosing regimen for aspirin chemoprevention of 1,2-dimethylhydrazine-induced colon tumours in rats
110. Chemopreventive efficacy of sulindac sulfone against colon cancer depends on time of administration during carcinogenic process
111. Sulindac sulfone inhibits azoxymethane-induced colon carcinogenesis in rats without reducing prostaglandin levels
112. Effect of aspirin on incidence and growth of aberrant cypt foci induced in the rat colon by 1,2-dimethylhydrazine
113. Inhibition of aberrant crypt growth by non-steroidal anti-inflammatory agents and differentiation agents in the rat colon
114. Evaluation of cyclooxygenase-2 inhibitor for potential chemopreventative properties in colon carcinogenesis
115. Piroxicam-induced regression of azoxymethane-induced aberrant crypt foci and prevention of colon cancer in rats
116. Suppression of azoxymethane-induced aberrant crypt foci in rat colon by nimesulide, a selective inhibitor of cyclooxygenase 2
117. Colorectal cancer
118. Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis
119. Human esophageal carcinoma cell lines: Prostaglandin production, biological properties, and behavior in nude mice
120. Expression of cyclooxygenase-1 and cyclooxygenase-2 in NMBA-induced rat esophageal tumorigenesis [abstract]
121. Aspirin induction of apoptosis in esophageal cancer: A potential for chemoprevention
122. 2 on gastrointestinal tumorigenesis induced by N-methyl-N'-nitro-N-nitrosoguanidine in rats. I. Squamous epithelium and mesenchymal tissue
123. Modification of BHA forestomach carcinogenesis in rats: Inhibition by diethylmaleate or indomethacin and enhancement by a retinoid
124. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, and indomethacin against ultraviolet light-induced skin carcinogenesis
125. Cyclooxygenase inhibitors retard murine mammary tumor progression by reducing tumor cell migration, invasiveness and angiogenesis
126. Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice
127. Chemotherapeutic evaluation of Celecoxib, a cyclooxygenase-2 inhibitor, in a rat mammary tumor model
128. Chemoprevention by nimesulide, a selective cyclooxygenase-2 inhibitor, of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP)-induced mammary gland carcinogenesis in rats
129. Inhibition of COX-2 and induction of a apoptosis: Two determinants of nonsteroidal and anti-inflammatory drugs' chemopreventive efficacies in mouse lung tumorigenesis
130. Meloxicam inhibits the growth of non-small cell lung cancer
131. Chemoprevention efficacies of aspirin and sulindac against lung tumorigenesis in A/J mice
132. Prevention of NNK-induced lung tumorigenesis in A/J mice by acetylsalicylic acid and NS-398
133. Induction of prostaglandin G/H synthase-2 in a canine model of spontaneous prostatic adenocarcinoma
134. Inhibition of cyclooxygenase-2 suppresses angiogenesis and the growth of prostate cancer in vivo
135. Chemopreventive effects of nimesulide, a selective cyclooxygenase-2 inhibitor, on the development of rat urinary bladder carcinomas initiated by N-butyl-N-(4-hydroxybutyl)nitrosamine
136. Celecoxib inhibits N-butyl-N-(4-hydroxybutyl)-nitrosamine-induced urinary bladder cancers in male B6D2F1 mice and female Fischer-344 rats
137. Acetylsalicylic acid inhibition of N-butyl-(4-hydroxybutyl)nitrosamine-induced bladder carcinogenesis in rats
138. NSAID-induced polyp regression in familial adenomatous polyposis patients
139. Rectal cancer after prolonged sulindac chemoprevention. A case report
140. Sulindac in familial adenomatous polyposis [letter]
141. Effect of sulindac on sporadic colonic polyps
142. United States-Japan workshop on New Rodent Models for the Analysis and Prevention of Carcinogenesis
143. The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis
144. Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis
145. Sulindac causes rapid regression of preexisting tumors in Min/+ mice independent of prostaglandin biosynthesis
146. Genotype-phenotype correlation in murine Apc mutation: Differences in enterocyte migration and response to sulindac
147. Aspirin prevents tumors in a murine model of familial adenomatous polyposis
148. (delta)716 mouse by rofecoxib, a specific cyclooxygenase-2 inhibitor
149. Aspirin, NSAIDs, and digestive tract cancers
150. Aspirin and other nonsteroidal antiinflammatory drugs and the risk of cancer development
151. Aspirin use and reduced risk of gastrointestinal tract cancers in the American Cancer Society prospective studies
152. Initial screening for carcinogenicity of commonly used drugs
153. Prospective study of regular aspirin use and the risk of breast cancer
154. Prospective study of nonsteroidal anti-inflammatory drugs and breast cancer
155. Nested case-control study of the effects of non-steroidal anti-inflammatory drugs on breast cancer risk and stage
156. Breast cancer and NSAID use: A meta-analysis
157. Non-steroidal anti-inflammatory drugs and prostate cancer progression
158. Over-the-counter analgesics and risk of ovarian cancer
159. Paracetamol and risk of ovarian cancer mortality in a prospective study of women in the USA [letter]
160. Aspirin and ovarian cancer: An Italian case-control study
161. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2
162. PPARdelta is an APC-regulated target of nonsteroidal anti-inflammatory drugs
163. Apoptosis
164. Apoptosis and APC in colorectal tumorigenesis
165. Colorectal tumors
166. Inhibition of apoptosis during development of colorectal cancer
167. The effects of sulindac on colorectal proliferation and apoptosis in familial adenomatous polyposis
168. Influence of meloxicam on loss of apoptotic activity during carcinogenesis [abstract]
169. Modulation of apoptosis by sulindac, curcumin, phenylethyl-3-methylcaffeate, and 6-phenyl-hexyl isothiocyanate: Apoptotic index as a biomarker in colon cancer chemoprevention and promotion
170. Induction of apoptosis by JTE-522, a specific cyclooxygenase-2 inhibitor, in human gastric cancer cell lines
171. Selective inhibition of cyclooxygenase-2 suppresses growth and induces apoptosis in human esophageal adenocarcinoma cells
172. Specific inhibition of cyclooxygenase-2 results in inhibition of proliferation of oral cancer cell lines via suppression of prostaglandin E2 production
173. Expression of cyclooxygenase 2 (COX-2) in human glioma and in vitro inhibition by a specific COX-2 inhibitor, NS-398
174. Increased cyclooxygenase-2 expression in human pancreatic carcinomas and cell lines: Growth inhibition by nonsteroidal anti-inflammatory drugs
175. Cancer research. Anti-inflammatories inhibit cancer growth-but how?
176. 1 delay in cells overexpressing prostaglandin endoperoxide synthase-2
177. Induction of apoptotic cell death in human colorectal carcinoma cell lines by a cyclooxygenase-2 (COX-2)-selective nonsteroidal anti-inflammatory drug: Independence from COX-2 protein
178. Nonsteroidal antiinflammatory drugs inhibit the proliferation of colon adenocarcinoma cells: Effects on cell cycle and apoptosis
179. Sulindac sulfide, an aspirin-like compound, inhibits proliferation, causes cell cycle quiescence, and induces apoptosis in HT-29 colon adenocarcinoma cells
180. Up-regulation of cyclooxgenase 2 gene expression in human colorectal adenomas and adenocarcinomas
181. Size- and invasion-dependent increase in cyclooxygenase 2 levels in human colorectal carcinomas
182. Prostaglandin synthase 1 gene disruption in mice reduces arachidonic acid-induced inflammation and indomethacin-induced gastric ulceration
183. Cyclooxygenase knockout mice: Models for elucidating isoform-specific functions
184. Cyclooxygenase-selective inhibition of prostanoid formation: Transducing biochemical selectivity into clinical read-outs
185. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs
186. Intracellular unesterified arachidonic acid signals apoptosis
187. Mechanisms underlying nonsteroidal antiinflammatory drug-mediated apoptosis
188. Antineoplastic drugs sulindac sulfide and sulfone inhibit cell growth by inducing apoptosis
189. Identification of c-MYC as a target of the APC pathway
190. Inhibition of NF-kappa B by sodium salicylate and aspirin
191. Sulindac inhibits activation of the NF-kappaB pathway
192. Sodium salicylate induces apoptosis via p38 mitogen-activated protein kinase but inhibits tumor necrosis factor-induced c-Jun N-terminal kinase/stress-activated protein kinase activation
193. Activation of p38 mitogen-activated protein kinase by sodium salicylate leads to inhibition of tumor necrosis factor-induced IkappaB alpha phosphorylation and degradation
194. A nuclear receptor to prevent colon cancer
195. 15-Lipoxygenase-1 mediates nonsteroidal anti-inflammatory drug-induced apoptosis independently of cyclooxygenase-2 in colon cancer cells
196. Cyclooxygenase regulates angiogenesis induced by colon cancer cells
197. Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: Insight into mechanisms and implications for cancer growth and ulcer healing
198. Cyclooxygenase-2 inhibitors: A new class of anti-inflammatory agents that spare the gastrointestinal tract
199. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF
200. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors
201. Host cyclooxygenase-2 modulates carcinoma growth
202. Suppression of human colorectal mucosal prostaglandins: Determining the lowest effective aspirin dose
203. Phase I chemoprevention study of piroxicam and alpha-difluoromethylornithine
204. Effects of piroxicam on prostaglandin E2 levels in rectal mucosa of adenomatous polyp patients: A randomized phase IIb trial
205. Effect of subacute ibuprofen dosing on rectal mucosal prostaglandin E2 levels in healthy subjects with a history of resected polyps
206. Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor
207. Expression of cyclooxygenase-2 in human gastric carcinoma
208. Expression of cyclooxygenase-2 (COX-2) in human invasive transitional cell carcinoma (TCC) of the urinary bladder
209. Increased expression of cyclooxygenase-2 in human pancreatic neoplasms and potential for chemoprevention by cyclooxygenase inhibitors
210. Non-steroidal anti-inflammatory drugs and bladder cancer prevention
211. Celecoxib prevents tumor growth in vivo without toxicity to normal gut: Lack of correlation between in vitro and in vivo models
212. Enhanced antitumor activity by co-administration of celecoxib and the chemotherapeutic agents cyclophosphamide and 5-FU [abstract]
213. Enhancement of tumor response to gamma radiation by an inhibitor of cyclooxygenase-2 enzymeb
214. The relationship between cyclooxygenase-2 expression and colorectal cancer
215. Is cyclooxygenase-2 the alpha and the omega in cancer?
216. Recent advances in chemoprevention of cancer
217. Mechanism-based target identification and drug discovery in cancer research